Epidermal growth factor receptor, c-kit, and her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 world health organization in patients treated with octreotide and prednisone: an eastern cooperative oncology group study

Journal of Thoracic Oncology

Volumn 5, Issue 6, 2010, Pages 885-892

  Aisner, Seena C ^a   Dahlberg, Suzanne ^b   Hameed, Meera R ^a   Ettinger, David S ^c   Schiller, Joan H ^d   Johnson, David H ^e   Aisner, Joseph ^f   Loehrer, Patrick J ^g  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e VANDERBILT INGRAM CANCER CENTER   (United States)

^f RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

2004 WHO classification of thymoma; C kit; EGFR; Her2 neu; Octreotide; Thymic epithelial neoplasms; Thymoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; OCTREOTIDE; PREDNISONE; STEM CELL FACTOR; TUMOR MARKER; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ERBB2 PROTEIN, HUMAN; STEM CELL FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CELL; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THYMIC EPITHELIAL NEOPLASM; THYMUS CANCER; WORLD HEALTH ORGANIZATION; CHEMISTRY; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; NEOPLASMS, GLANDULAR AND EPITHELIAL; PATHOLOGY; THYMUS NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OCTREOTIDE; PREDNISONE; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; THYMUS NEOPLASMS; WORLD HEALTH ORGANIZATION;

EID: 77953135321     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d86a30     Document Type: Article

References (24)

1. Marino M, Muller-Hermelink HK. Thymoma and thymus carcinoma. Relation of thymus epithelial cells to the cortical and medullary differentiation of the thymus. Virchows Arch A Pathol Anat Histopathol 1985;407:119-149.
2. Masaoka A, Monden Y, Kazuya N, et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485-2492.
3. Suster S, Moran CA. Thymoma, atypical thymoma and thymic carcinoma. A novel conceptual approach to the classification of thymic epithelial neoplasms. Am J Clin Pathol 1999;111:826-833.
4. Muller-Hermelink HK, Engel P, Kuo TT, et al. Tumors of the thymus: introduction. In Travis WD, Brambilla E, Muller-Hermelink HK, et al. (Eds.), Pathology and Genetics. Tumors of the Lung, Pleura, Thymus and Heart. WHO Classification of Tumors. Lyon: IARC Press, 2004. Pp. 146-247.
5. Palmieri G, Lastoria S, Colao A, et al. Successful treatment of a patient with a thymoma and pure red cell aplasia with octreotide and prednisone. NEJM 1997;336:263-265.
6. Ellis IO, Pinder SE, Lee AHS. Tumors of the breast. In Fletcher CDM (Ed). Diagnostic Histopathology of Tumors, 3rd Ed. New York: Churchill Livingstone, 2007. Pp. 903-969.
7. Henley JD, Koukoulis GK, Loehrer PJ. Epidermal growth factor receptor expression in invasive thymoma. J Cancer Res Clin Oncol 2002;129:167-170.
8. Sovak M, Aisner J, Aisner S. Tumors of the pleura and mediastinum. In: Abeloff's, Clinical Oncology, 4th Ed. Philadelphia, PA: Churchill Livingstone, 2008. Pp. 1367-1398.
9. Detterbeck FC. Clinical value of the WHO classification system of thymoma. Ann Thorac Surg 2006;81:2328-2334.
10. Rena O, Papalia E, Maggi G, et al. World Health Organization histologic classification: an independent prognostic factor in resected thymomas. Lung Cancer 2005;50:59-66.
11. Strobel P, Marx A, Zeitl A, et al. Thymoma and thymic carcinoma: an update of the WHO classification 2004. Surg Today 2005;35:805-811.
12. Ionsecu DN, Sastomi E, Cieply K. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 2005;103:3630-3636.
13. Meister M, Schirmacher P, Dienemann H, et al. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. Cancer Letters 2007;248:186-191.
14. Yoh K, Nishiwaki Y, Ishii G, et al. Mutational status of EGFR and Kit in thymoma and thymic carcinoma. Lung Cancer 2008;62:316-320.
15. Henley J, Cummings O, Loehrer P. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 2004;130:222-224.
16. Suzuki E, Sasaki, H, Kawano O, et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 2006;36:351-356.
17. Carpenter G. Receptors of epidermal growth factor and other polypeptide mitogens. Ann Rev Biochem 1987;56:881-914.
18. Laskin JJ, Sandler AB. Epidermal growth factor receptor: a promising target in solid tumors. Can Treat Rev 2004;30:1-17.
19. Palmieri G, Marino M, Salvatore M, et al. Cetuximab in an active treatment of metastatic and chemorefractory thymoma. Front Biosci 2007;12:757-761.
20. Strobel P, Hartmann M, Jakob A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. NEJM 2004;350:2625-2626.
21. Giaccone G, Wilmink H, Paul M, et al. Systemic treatment of malignant thymoma. Am J Clin Oncol 2006;29:336-344.
22. Salter JT, Lewis D, Yiannoutsos P, et al. Imatinib for the treatment of thymic carcinoma. J Clin Oncol 2008;26 (suppl) : abstr 8116.
23. Kurup A, Burns M, Dropcho S. Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol 2005;23 (suppl) : abstr 7068.
24. Bedano PM, Perkins S, Burns M, et al. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma of thymic carcinoma. J Clin Oncol 2008;26 (suppl) : abstr 19087.